Advanced Search

 

Study ID Status Title Patient Level Data
104864/511 Completed A Phase I open label study to assess the safety, tolerability, and efficacy of oral etoposide and oral topotecan administered in combination to patients with small-cell lung cancer who have not previously received chemotherapy
104864/517 Terminated A Phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer
104864/535 Completed A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
104864/612 Completed A prospective, open label phase II study to evaluate the efficacy and safety of topotecan (Hycamtin) in combination with carboplatin as first-line chemotherapy in patients with ovarian cancer.
104864/615 Completed WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL
104864/623 Completed An Open Label, Multicenter, Non-Comparative Phase II Study of Weekly Intravenous Vinorelbine and Topotecan in Chemotherapy-Nave Patients with Advanced Non-Small Cell Lung Cancer
104864/627 Completed An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients with Recurrent Platinum Sensitive Ovarian Cancer
104864/692 Completed A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients with Advanced Solid Tumors
104864/902 Completed An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 every 21 days) HYCAMTIN in Combination with Carboplatin (Day 1 every 21 days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer
104864/903 Completed An open-label phase II study of weekly intravenous Hycamtin and carboplatin as first-line treatment of chemonaive subjects with Extensive Disease Small Cell lung Cancer
104864-A/387 Completed An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients with Pretreated Advanced Non Small Cell Lung Cancer
104864-A/389 Completed An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer.
104864-A/479 Completed An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer
104871 Completed A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children Study Listed on ClinicalStudyDataRequest.com
104886 Completed Demonstrate the non-inferiority in term of cellular mediated immune response of GSK Biologicals' influenza candidate vaccines containing various adjuvants administered in elderly population (aged 65 years & older) vs Fluarix™ (known as alpha-Rix™ in Belgium) administered in adults (18-40 years) Study Listed on ClinicalStudyDataRequest.com
104887 Completed Evaluate reactogenicity & immunogenicity of adjuvanted influenza vaccine in elderly adults previously vaccinated with the same candidate vaccine. Fluarix™ administered in young & elderly adults will be used as reference Study Listed on ClinicalStudyDataRequest.com
104888 Completed A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™ Study Listed on ClinicalStudyDataRequest.com
104951 Completed Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs Study Listed on ClinicalStudyDataRequest.com
104972 Completed A randomised (with respect to placebo), double-blind, placebo-controlled, adaptive dose ascending study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK315234A (a humanised monoclonal antibody to oncostatin M) in patients with active rheumatoid arthritis (RA) Study Listed on ClinicalStudyDataRequest.com
104977 Completed Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age Study Listed on ClinicalStudyDataRequest.com
105012 Completed Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Study Listed on ClinicalStudyDataRequest.com
105-040 Completed A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients Study Listed on ClinicalStudyDataRequest.com
105043/013 Completed An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
105095 Completed An open-label, randomized (with respect to different doses of casopitant), two-period parallel group study to evaluate the potential pharmacokinetic interaction of co-administered casopitant and digoxin in healthy subjects Study Listed on ClinicalStudyDataRequest.com
105120 Completed An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co-administered with Eltrombopag (SB-497115-GR) in Healthy Adult Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.